Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03357796 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03357796 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 20 participants.
The verdict
NCT03357796, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
Interventions
- DRUG LY03005
- DRUG Pristiq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03357796
The ClinicalTrials.gov registry entry for NCT03357796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LY03005 is the first listed.
NCT03357796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03357796 about?
NCT03357796 is a clinical study titled "Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®". The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
What is the current status of trial NCT03357796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-11-27. Estimated completion is 2017-12-22.
What interventions are being tested in trial NCT03357796?
The interventions under investigation include: LY03005 (DRUG), Pristiq (DRUG).
Who is sponsoring clinical trial NCT03357796?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.